Italia markets close in 6 hours 58 minutes

Sanofi (0A2V.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
49,56-0,51 (-1,02%)
In data: 07:00PM BST. Mercato aperto.
Schermo intero
Chiusura precedente50,07
Aperto49,18
DenaroN/D x N/D
DomandaN/D x N/D
Min-Max giorno49,18 - 49,28
Intervallo di 52 settimane36,99 - 57,78
Volume0
Media Volume20.422
CapitalizzazioneN/D
Beta (mensile su 5 anni)0,44
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili25 lug 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

    Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Patients treated with amlitelimab experienced up to 61.5% improvement in average Eczema Area and Severity Index (EASI) score from baseline at week 16, the primary endpoint, with continued improvement seen through 24 weeksClinically meaningful improvements were seen in all key secondary endpoints at week 16 with continued improvements through week 24, including for IGA 0/1 where pat

  • GlobeNewswire

    Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

    Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s diseaseCollaboration supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseasesCollaboration leverages the innovative R&D and commercial expertise of both companies Paris, France and Parsippany, New Jersey, October 4, 2023. Sanofi (EURONEXT: SAN and NASDA

  • GlobeNewswire

    Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

    Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease (IED) annually, worldwide1,2Phase 3 clinical trial of vaccine candidate ongoing. Novel ExPEC vaccine expected to complement existing older adult vaccine portfolio Paris, October 3, 2023. Sanofi announces today that it has entered into an agreeme